Drugs

Pharmacogenomic Information on Hydralazine

Pharmacogenomic Information
  

 DrugTherapeutic Area*BiomarkerReferenced
Subgroup‡ 
Labeling Sections
HydralazineCardiologyNAT1-2NAT1-2 slow acetylatorsClinical Pharmacology

 

* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.
‡ Common terminology listed based on available data with labeling language in parentheses.

 

back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 08/15/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.